ORIGINAL ARTICLE
Open Access

Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer

Elise Martin, ORCID1, Arnaud Leclerc2, Jean-Luc Moreau3 , Céline Roche4

1 Department of General and Endocrine Surgery, Medical University of Warsaw.
2 Department of Surgical Oncology, Hôpital Saint-Louis, Paris.
3 Institut Bergonié, Bordeaux
4 Department of Medical Oncology, Hôpital Saint-Louis

DOI: 10.18081/ajbm.2025.3.145

Publication History: Received 20 April 2025, Revised 07 May 2025, Accepted 15 June 2025, Available online 04 July 2025
Copyright: © 2025 Martin, et al. This is an open-access article under a Creative Commons license (CC BY 4.0).

Crossmark logo

Background: Despite significant advances in systemic therapy, the optimal surgical extent for locally advanced breast cancer (LABC) remains debated. While the Radical Mastectomy (RM) has largely been replaced by the Modified Radical Mastectomy (MRM), RM continues to be performed for select cases involving chest wall or pectoral muscle invasion. This multicenter prospective study compared the oncologic, functional, and quality-of-life outcomes of RM and MRM in patients with LABC treated in French tertiary centers.

Methods: A prospective comparative cohort study was conducted between January 2018 and December 2024 across three French surgical oncology centers. A total of 200 patients with stage IIIA–IIIC (T3–T4, N2–N3, M0) LABC were enrolled; 180 were analyzed after propensity matching (RM: n=90; MRM: n=90). All patients received neoadjuvant anthracycline–taxane chemotherapy, followed by either RM (Halsted–Meyer technique) or MRM (Patey/Auchincloss). Primary endpoints were Disease-Free Survival (DFS) and Overall Survival (OS); secondary endpoints included postoperative complications, functional recovery, and quality of life (QoL) assessed using the EORTC QLQ-C30/BR23 instruments. Statistical comparisons were made using the t-test, χ² test, Kaplan–Meier survival analysis, and Cox regression modeling (P < 0.05 significant).

Results: Baseline demographics were comparable between groups. RM was associated with longer operative time (132.6 ± 22.4 vs. 108.2 ± 18.5 min, P < 0.001) and higher morbidity (28.9% vs. 13.3%, P = 0.012). The 3-year DFS was 78.9% (RM) vs. 82.2% (MRM) (P = 0.47) and 3-year OS 86.7% vs. 89.4% (P = 0.52). Lymphedema (12.2% vs. 4.4%, P = 0.048) and shoulder stiffness (14.4% vs. 5.6%, P = 0.036) were significantly higher after RM. QoL scores favored MRM in physical, body image, and emotional domains (P < 0.001). Multivariate analysis identified tumor size ≥6 cm, lymphovascular invasion, and triple-negative subtype as independent predictors of recurrence, not surgical type.

Conclusion: In the era of neoadjuvant and adjuvant multimodal therapy, Modified Radical Mastectomy achieves equivalent oncologic outcomes to Radical Mastectomy while offering superior functional recovery and quality of life. RM should be reserved for patients with confirmed pectoral muscle or chest wall invasion. These findings support French and European surgical guidelines prioritizing muscle-preserving approaches as the standard of care for operable LABC.

Keywords: Locally advanced breast cancer; Radical mastectomy; Modified radical mastectomy; Neoadjuvant chemotherapy.

Recommended Citation

Martin E, Leclerc A , Roche C, Moreau JL. Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer. Advanced Journal of Biomedicine & Medicine. 2025;13(3):144-162. doi:10.18081/ajbm.2025.3.145

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

References

  1. Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. Ann Surg. 1894;20(5):497-555. doi:10.1097/00000658-189411000-00075
  2. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241. doi:10.1056/NEJMoa022152
  3. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232. doi:10.1056/NEJMoa020989
  4. Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer. 1948;2(1):7-13. doi:10.1038/bjc.1948.2
  5. Auchincloss H Jr. Modified radical mastectomy with preservation of the pectoral muscles. Ann Surg. 1948;128(4):587-600. doi:10.1097/00000658-194810000-00009
  6. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-575. doi:10.1056/NEJMoa020128
  7. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6-11. doi:10.1056/NEJM198107023050102
  8. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(14):956-962. doi:10.1056/NEJM199710023371402
  9. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337(14):949-955. doi:10.1056/NEJM199710023371401
  10. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(5):1539-1569. doi:10.1200/JCO.2001.19.5.1539
  11. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on recurrence and 15-year survival: meta-analysis of 22 trials. 2014;383(9935):2127-2135. doi:10.1016/S0140-6736(14)60488-8
  12. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in breast cancer? J Clin Oncol. 2002;20(3):568-574. doi:10.1200/JCO.2002.20.3.568
  13. Raina V, Bhutani M, Bedi R, et al. Locally advanced breast cancer: results of modified radical mastectomy versus radical mastectomy in a randomized trial. Indian J Cancer. 2001;38(2-4):62-68. doi:10.4103/0019-509X.27945
  14. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer. Lancet Oncol. 2018;19(1):27-39. doi:10.1016/S1470-2045(17)30777-5
  15. Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international expert panel on the use of neoadjuvant therapy in primary breast cancer. Ann Oncol. 2012;23(6):1426-1433. doi:10.1093/annonc/mds232
  16. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm. 1999;85(12):3073-3080. doi:10.1002/(SICI)1097-0142(19990615)85:12<3073::AID-CNCR19>3.0.CO;2-8
  17. Montagna G, Mamtani A, Eaton A, et al. Outcomes of skin-sparing mastectomy after neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(9):3306-3314. doi:10.1245/s10434-020-08453-2
  18. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2019;30(8):1194-1220. doi:10.1093/annonc/mdz173
  19. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference. Ann Oncol. 2017;28(8):1700-1712. doi:10.1093/annonc/mdx308
  20. Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on surgical management. JAMA Surg. 2013;148(9):940-946. doi:10.1001/jamasurg.2013.2827
  21. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94(10):1189-1200. doi:10.1002/bjs.5874
  22. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304(1):10-15. doi:10.1056/NEJM198101013040103
  23. Ciatto S, Houssami N, Bonardi R, et al. Integration of MRI in breast cancer staging and treatment. Breast Cancer Res Treat. 2007;106(2):179-185. doi:10.1007/s10549-006-9482-2
  24. Ewertz M, Jensen MB, Gunnarsdóttir KÁ, et al. Post-treatment arm lymphedema and pain among breast cancer survivors. Acta Oncol. 2010;49(7):1091-1099. doi:10.3109/02841861003753722
  25. Peintinger F, Reitsamer R, Stranzl H, et al. Comparison of modified radical mastectomy versus radical mastectomy in LABC. 2003;12(3):207-211. doi:10.1016/S0960-9776(03)00013-7
  26. Arriagada R, Rutqvist LE, Kramar A, et al. Competing risks of death after adjuvant therapy in early breast cancer. J Clin Oncol. 1992;10(10):1551-1558. doi:10.1200/JCO.1992.10.10.1551
  27. Giordano SH, Elias AD, Gradishar WJ. NCCN Guidelines Update: Breast Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(5):331-357. doi:10.6004/jnccn.2024.0021
  28. Ewertz M, Jensen MB, Nielsen D, et al. Quality of life in breast cancer survivors following different surgical approaches. Eur J Surg Oncol. 2016;42(12):1782-1788. doi:10.1016/j.ejso.2016.08.018
  29. Cardoso MJ, Fernandes A, González-Martín A, et al. European audit on breast reconstructive surgery after mastectomy. Eur J Cancer. 2017;72:39-50. doi:10.1016/j.ejca.2016.11.029
  30. ESMO–EUSOMA. Breast cancer multidisciplinary recommendations. Ann Oncol. 2022;33(2):115-132. doi:10.1093/annonc/mdab576
  31. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3
  32. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281. doi:10.1200/JCO.2007.14.4147
  33. Kuerer HM, Hunt KK, Newman LA, et al. Neoadjuvant chemotherapy in locally advanced breast cancer: results of combined-modality therapy. J Clin Oncol. 1999;17(2):460-469. doi:10.1200/JCO.1999.17.2.460
  34. Montagna E, Cancello G, Pagan E, et al. Survival outcomes for locally advanced breast cancer after modern systemic therapy. 2018;37:78-84. doi:10.1016/j.breast.2017.10.013
  35. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122-137. doi:10.1056/NEJMoa1803164
  36. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Int Agency Res Cancer (IARC). doi:10.1002/ijc.33588
  37. Fitzal F, Mittlböck M, Gnant M. Breast cancer surgery: standards and controversies. Breast Care. 2019;14(3):123-129. doi:10.1159/000499476
  38. de Boniface J, Szulkin R, Johansson ALV. Survival after breast-conserving therapy versus mastectomy for early breast cancer. Eur J Cancer. 2021;143:58-71. doi:10.1016/j.ejca.2020.11.017
  39. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer. J Clin Oncol. 2001;19(22):4224-4237. doi:10.1200/JCO.2001.19.22.4224
  40. Clough KB, Oden S, Gouveia PF, et al. Oncoplastic surgery for breast cancer: the French experience and current practice. Breast J. 2020;26(6):1163-1172. doi:10.1111/tbj.13756

2025 Vol 13, Issue 3 Pages 145-162

Download article

PDF Download: 887

PDF (490.0 KB) XML (4.4 KB)

Cite this article

Elise Martin, Arnaud Leclerc, Jean-Luc Moreau, Céline Roche (2025). Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer. Advanced Journal of Biomedicine & Medicine, 13(3), 145-161. https://doi.org/ 10. 10.18081/ajbm.2025.3.145
Elise Martin, Arnaud Leclerc, Jean-Luc Moreau, Céline Roche. "Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer." Advanced Journal of Biomedicine & Medicine, vol. 13, no. 3, 2025, pp. 145-161. DOI: 10. 10.18081/ajbm.2025.3.145.
Elise Martin, Arnaud Leclerc, Jean-Luc Moreau, Céline Roche. Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer. AJBM. 2025;13(3):145-161. DOI: 10. 10.18081/ajbm.2025.3.145. PMID: .
Elise Martin, Arnaud Leclerc, Jean-Luc Moreau, Céline Roche 2025, "Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer", Advanced Journal of Biomedicine & Medicine, vol. 13, no. 3, pp. 145-161.
@article{elise2025, title={Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer}, author={Elise Martin, Arnaud Leclerc, Jean-Luc Moreau, Céline Roche}, journal={Advanced Journal of Biomedicine & Medicine}, volume={13}, number={3}, pages={145-161}, year={2025}, doi={ 10. 10.18081/ajbm.2025.3.145} }
TY - JOUR AU - Elise Martin, Arnaud Leclerc, Jean-Luc Moreau, Céline Roche TI - Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer JO - American Journal of Biomedicine VL - 13 IS - 3 SP - 145-161 PY - 2025 DO - 10. 10.18081/ajbm.2025.3.145 ER -
%0 Journal Article %A Elise Martin, Arnaud Leclerc, Jean-Luc Moreau, Céline Roche %T Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer %J American Journal of Biomedicine %V 13 %N 3 %P 145-161 %D 2025 %R 10. 10.18081/ajbm.2025.3.145 %M
Elise Martin, Arnaud Leclerc, Jean-Luc Moreau, Céline Roche (2025). Outcomes of Radical Mastectomy Versus Modified Radical Mastectomy in Locally Advanced Breast Cancer. Advanced Journal of Biomedicine & Medicine, 13(3), 145-161. https://doi.org/ 10. 10.18081/ajbm.2025.3.145

Article metric